This prospective, observational, multicenter study will assess the efficacy and safety of RoActemra/Actemra (tocilizumab) on the use of glucocorticoids in patients with moderate to severe rheumatoid arthritis and an inadequate response to previous disease-modifying antirheumatic drugs or anti-TNF. Data will be collected for 36 weeks.
Read more: http://www.clinicaltrials.gov/ct2/show/NCT01564901?cond=%22Arthritis%22&lup_s=01/29/2014&lup_d=30
